Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy

被引：0
|
作者：
Finnigan, John P. [1 ]
Rubinsteyn, Alex [2 ]
Hannmerbacher, Jeffrey [2 ]
Bhardwaj, Nina [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA
来源：
ONCOLOGY-NEW YORK | 2015年 / 29卷 / 12期
关键词：
CYTOLYTIC T-LYMPHOCYTES; EXOME ANALYSIS REVEALS; CTLA-4; BLOCKADE; POINT MUTATION; PD-1; GENE ENCODES; PHASE-II; MELANOMA; CELLS; EPITOPES;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：970 / +
页数：5
相关论文
共 50 条
  • [1] Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma
    Perumal, Deepak
    Lagana, Alessandro
    Rubinsteyn, Alex
    Finnigan, John P., Jr.
    Kuo, Pei-Yu
    Leshchenko, Violetta V.
    Chari, Ajai
    Cho, Hearn Jay
    Jagannath, Sundar
    Dudley, Joel
    Hammerbacher, Jeff
    Schadt, Eric
    Bhardwaj, Nina
    Parekh, Samir
    BLOOD, 2015, 126 (23)
  • [2] Mutation-Derived Neoantigens for Cancer Immunotherapy
    Castle, John C.
    Uduman, Mohamed
    Pabla, Simarjot
    Stein, Robert B.
    Buell, Jennifer S.
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [3] Mutated tumor antigens as targets for cancer immunotherapy
    Prommersberger, S.
    Hofflin, S.
    Gross, S.
    Schuler, G.
    Dorrie, J.
    Schaft, N.
    EXPERIMENTAL DERMATOLOGY, 2012, 21 (03) : e27 - e27
  • [4] Immune response towards mutation-derived tumor antigens in bladder cancer patients treated with CTLA-4 blockade
    Saito, Takuro
    Gnjatic, Sacha
    Kishi, Kentaro
    Tanemura, Masahiro
    Akamatsu, Hiroki
    Uzilov, Andrew
    Galsky, Matthew
    Bhardwaj, Nina
    CANCER SCIENCE, 2018, 109 : 946 - 946
  • [5] Immunoregulatory antigens-novel targets for cancer immunotherapy
    Pedersen, Ayako Wakatsuki
    Kopp, Katharina L.
    Andersen, Mads Hald
    Zocca, Mai-Britt
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (02)
  • [6] Analyses of novel tumour antigens as targets for cancer immunotherapy
    Silina, K.
    Kalnina, Z.
    Meistere, I.
    Zayakin, P.
    Abols, A.
    Rivosh, A.
    Line, A.
    EJC SUPPLEMENTS, 2008, 6 (09): : 168 - 168
  • [7] Universal tumor antigens as targets for immunotherapy
    Gordan, JD
    Vonderheide, RH
    CYTOTHERAPY, 2002, 4 (04) : 317 - 327
  • [8] Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies
    Aparicio, Belen
    Theunissen, Patrick
    Hervas-Stubbs, Sandra
    Fortes, Puri
    Sarobe, Pablo
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [9] TUMOR-ASSOCIATED ANTIGENS AS IMMUNOTHERAPY TARGETS
    PHILLIPS, NC
    MAJOR, PP
    SIKORSKA, H
    CANCER DETECTION AND PREVENTION, 1988, 12 (1-6): : 451 - 459
  • [10] Global impact of mutation-derived varieties
    B.S. Ahloowalia
    M. Maluszynski
    K. Nichterlein
    Euphytica, 2004, 135 : 187 - 204
12345